A Phase 1 interventional study of Cisplatin and S-1 in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-03-13.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies testing cisplatin in Stomach Neoplasms — 7 open to participants now, 8 under way, 2 of them phase 3. Cisplatin · Stomach Neoplasms.
Among the 98 studies testing cisplatin in Stomach Neoplasms, this one is the 73rd largest by enrollment of the 90 interventional ones that give a count, is one of 8 that started in 2007, is one of 14 in phase 1, and was the 44th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →7 of the 98 studies testing cisplatin in Stomach Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18+
Krankenhaus Nordwest · Sites in Germany
Ages 18–75
City of Hope Medical Center · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18–80
Odense University Hospital · Sites in United States, Denmark, France and 2 more countries
Ages 18–80
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 67 · Phase 3 16
First in 1994; this study’s year is marked. 8 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 48 across the 90 interventional studies. Of the 76 that completed or were terminated, 27 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 98 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
27 studies in Stomach Neoplasms by Pfizer: 5 open now, 7 under way, 1 of them phase 3. Of 20 finished, 10 (50%) have results posted.
Among the 27 studies in Stomach Neoplasms by Pfizer, this one is the 22nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2007, is one of 18 in phase 1, and was the 4th registered.
Pfizer’s Stomach Neoplasms studies by the year they started, since 2002.
2 of the studies testing cisplatin in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06295094Odense University HospitalThe Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. | 2027-01 |
| NCT07139951Mayo ClinicHyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | 2027-05-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 98 studies testing cisplatin in Stomach Neoplasms, from their registry updates:
Among Pfizer’s 27 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
To assess the maximal tolerated dose (MTD) and overall safety of sunitinib when administered in combination with S-1 and Cisplatin in patients with advanced/metastatic gastric cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cisplatin · Drug: S-1 · Drug: Sunitinib
Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Drug pages: Tegafur · Gimeracil · Oxonic Acid
S-1 80 mg/m2 on days 1-21 of each 28 day cycle
Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
Number of Participants With First Cycle Dose-limiting Toxicities (DLTs)
A DLT is any of a predefined set of unacceptable adverse events, regardless of cause. DLTs were assessed during the first cycle (4 weeks).
Time frame: Cycle 1 (Baseline to Week 4)
Maximum Observed Plasma Concentration (Cmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Sunitinib, SU-012662, and Total Drug (Sunitinib + SU-012662)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 2, 4, 6, 8, 10, and 24 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) of Tegafur and 5-FU
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Tegafur and 5-FU
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Tegafur and 5-FU
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 1, 2, 4, 6, 8, and 10 hours post-dose)
Maximum Observed Plasma Concentration (Cmax) of Total Platinum and Free Platinum
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Total Platinum and Free Platinum
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Total Platinum and Free Platinum
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Day 1 of Cycles 1 and 2 (pre-dose, 0.5, 1, 2, 8, and 22 hours after completing infusion)
Number of Participants With Objective Response
Number of participants with objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.
Time frame: Baseline up to 739 days
Number of Participants With Clinical Benefit Response (CBR)
CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.
Time frame: Baseline up to 739 days
Duration of Response (DR)
Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to cancer. DR calculated as (the end date for DR minus first subsequent confirmed CR or PR plus 1 day).
Time frame: Baseline up to 739 days
Progression-Free Survival (PFS)
Median time from the enrollment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (first event date minus enrollment date plus 1 day)
Time frame: Baseline up to 739 days
Time to Progression (TTP)
Time in months from enrollment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of enrollment plus 1 day). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
Time frame: Baseline up to 739 days
| Milestone | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Started | 4 | 16 | 6 | 1 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 4 | 16 | 6 | 1 |
| Withdrew: Adverse event | 2 | 4 | 0 | 1 |
| Withdrew: Global deterioration of health status | 0 | 2 | 0 | 0 |
| Withdrew: Objective progression or relapse | 2 | 9 | 6 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
A DLT is any of a predefined set of unacceptable adverse events, regardless of cause. DLTs were assessed during the first cycle (4 weeks).
| participants | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (Dose Escalation Cohort) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin |
|---|---|---|---|
| Number of Participants With First Cycle Dose-limiting Toxicities (DLTs) | 2 | 1 | 3 |
| nanogram per milliliter (ng/mL) | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) |
|---|---|
| Cycle 1 Day 1: Sunitinib (Sunitinib Alone) | 14.47 ± 5.3414 |
| Cycle 2 Day 1:Sunitinib (Sunitinib+S-1+Cisplatin) | 13.14 ± 3.1675 |
| Cycle 1 Day 1: SU-012662 (Sunitinib Alone) | 2.487 ± 1.1515 |
| Cycle 2 Day 1:SU-012662(Sunitinib+S-1+Cisplatin) | 2.331 ± 1.2943 |
| Cycle1 Day 1:Total Drug (Sunitinib Alone) | 16.86 ± 6.3194 |
| Cycle 2 Day 1:Total Drug(Sunitinib+S-1+Cisplatin) | 15.41 ± 3.7667 |
| hrs | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) |
|---|---|
| Cycle 1 Day 1: Sunitinib ( Sunitinib Alone) | 5.97 (3.83 to 8.00) |
| Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin) | 7.97 (3.97 to 9.93) |
| Cycle 1 Day 1: SU-012662 ( Sunitinib Alone) | 8.00 (3.83 to 10.1) |
| Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin) | 9.25 (5.97 to 23.8) |
| Cycle1 Day1:Total Drug ( Sunitinib Alone) | 5.97 (3.83 to 9.22) |
| Cycle 2 Day 1:Total Drug (Sunitinib+S-1+Cisplatin) | 7.92 (3.97 to 9.25) |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*h/mL | Sunitinib 25 mg 2/2 + Cisplatin + S-1 (MTD Expansion Cohort) |
|---|---|
| Cycle 1 Day 1: Sunitinib (Sunitinib Alone) | 214.6 ± 61.682 |
| Cycle 2 Day 1: Sunitinib (Sunitinib+S-1+Cisplatin) | 211.9 ± 46.092 |
| Cycle 1 Day 1: SU-012662 (Sunitinib Alone) | 39.77 ± 12.857 |
| Cycle 2 Day 1: SU-012662 (Sunitinib+S-1+Cisplatin) | 44.83 ± 24.046 |
| Cycle 1 Day 1: Total Drug (Sunitinib Alone) | 254.4 ± 70.913 |
| Cycle 2 Day 1:Total Drug (Sunitinib+S-1+Cisplatin) | 257.0 ± 59.324 |
| nanogram per milliliter (ng/mL) | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Tegafur (S-1 + Cisplatin) | 1500 ± 147.65 |
| Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin) | 1540 ± 184.39 |
| Cycle 1 Day 1: 5-FU (S-1 + Cisplatin) | 144.4 ± 33.901 |
| Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin) | 105.7 ± 19.318 |
| hrs | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Tegafur (S-1 + Cisplatin) | 1.98 (0.917 to 3.98) |
| Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin) | 2.00 (0.933 to 2.05) |
| Cycle 1 Day 1:5-FU (S-1 + Cisplatin) | 2.00 (1.98 to 3.98) |
| Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin) | 2.05 (2.00 to 4.13) |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*h/mL | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Tegafur (S-1 + Cisplatin) | 8314 ± 726.38 |
| Cycle 2 Day 1: Tegafur (Sunitinib+S-1+Cisplatin) | 9182 ± 819.65 |
| Cycle 1 Day 1: 5-FU (S-1 + Cisplatin) | 582.4 ± 109.12 |
| Cycle 2 Day 1: 5-FU (Sunitinib+S-1+Cisplatin) | 494.8 ± 124.14 |
| nanogram per milliliter (ng/mL) | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Total (S-1 + Cisplatin) | 1794 ± 140.11 |
| Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin) | 1984 ± 72.319 |
| Cycle 1 Day 1: Free (S-1 + Cisplatin) | 177.8 ± 121.47 |
| Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin) | 186.9 ± 139.45 |
| hrs | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Total (S-1 + Cisplatin) | 2.65 (2.50 to 2.93) |
| Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin) | 2.68 (2.58 to 2.90) |
| Cycle 1 Day 1: Free (S-1 + Cisplatin) | 2.65 (2.50 to 2.83) |
| Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin) | 2.68 (2.58 to 2.90) |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| ng*h/mL | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) |
|---|---|
| Cycle 1 Day 1: Total (S-1 + Cisplatin) | 29020 ± 2070.5 |
| Cycle 2 Day1: Total (Sunitinib+S-1+Cisplatin) | 33000 ± 2192.0 |
| Cycle 1 Day 1: Free (S-1 + Cisplatin) | 967.8 ± 332.03 |
| Cycle 2 Day 1:Free (Sunitinib+S-1+Cisplatin) | 1154 ± 417.55 |
Number of participants with objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.
| participants | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Number of Participants With Objective Response | 2 | 6 | 2 | 0 |
CBR is defined as a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD) for at least 24 weeks on study according to RECIST. Confirmed responses are those that persist on repeat imaging at least 4 weeks after initial documentation of response.
| participants | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Number of Participants With Clinical Benefit Response (CBR) | 2 | 12 | 4 | 0 |
Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to cancer. DR calculated as (the end date for DR minus first subsequent confirmed CR or PR plus 1 day).
| Months | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Duration of Response (DR) | 5.7 (5.4 to 5.9) | 10.4 (3.2 to NA) | 5.0 (4.6 to 5.3) | — |
Median time from the enrollment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (first event date minus enrollment date plus 1 day)
| Months | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Progression-Free Survival (PFS) | 7.1 (6.7 to 7.5) | 12.5 (6.4 to 16.5) | 5.8 (4.4 to 7.5) | — |
Time in months from enrollment to first documentation of objective tumor progression. TTP was calculated as (first event date or last known progression-free date minus the date of enrollment plus 1 day). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\] per RECIST).
| Months | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Time to Progression (TTP) | 7.1 (6.7 to 7.5) | 12.5 (6.4 to 16.5) | 5.8 (4.4 to 7.5) | — |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sunitinib 25 mg CDD + S-1 + Cisplatin | — | 2/4 (50%) | 4/4 (100%) |
| Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | — | 8/16 (50%) | 16/16 (100%) |
| Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | — | 2/6 (33.3%) | 6/6 (100%) |
| Sunitinib 12.5 mg CDD + S-1 + Cisplatin | — | 1/1 (100%) | 1/1 (100%) |
| Event | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| Cerebral infarctionNervous system disorders | 0/4 | 0/16 | 0/6 | 1/1 |
| Platelet count decreasedInvestigations | 2/4 | 2/16 | 0/6 | 0/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/4 | 3/16 | 2/6 | 0/1 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 1/4 | 1/16 | 0/6 | 0/1 |
| Cholecystitis acuteHepatobiliary disorders | 1/4 | 0/16 | 0/6 | 0/1 |
| AnaemiaBlood and lymphatic system disorders | 0/4 | 1/16 | 0/6 | 0/1 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/4 | 1/16 | 0/6 | 0/1 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 1/16 | 0/6 | 0/1 |
| BradycardiaCardiac disorders | 0/4 | 1/16 | 0/6 | 0/1 |
| PyrexiaGeneral disorders | 0/4 | 1/16 | 0/6 | 0/1 |
| Event | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/4 | 3/16 | 1/6 | 1/1 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/4 | 2/16 | 0/6 | 1/1 |
| LeukopeniaBlood and lymphatic system disorders | 0/4 | 3/16 | 1/6 | 1/1 |
| LymphopeniaBlood and lymphatic system disorders | 0/4 | 0/16 | 1/6 | 1/1 |
| NeutropeniaBlood and lymphatic system disorders | 0/4 | 3/16 | 1/6 | 1/1 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/4 | 3/16 | 1/6 | 1/1 |
| Lacrimation increasedEye disorders | 0/4 | 4/16 | 2/6 | 1/1 |
| DiarrhoeaGastrointestinal disorders | 4/4 | 8/16 | 4/6 | 0/1 |
| Dry mouthGastrointestinal disorders | 0/4 | 0/16 | 0/6 | 1/1 |
| Periodontal diseaseGastrointestinal disorders | 0/4 | 2/16 | 0/6 | 1/1 |
| Age, Continuous(years) | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin | Total |
|---|---|---|---|---|---|
| Mean | 60.8 ± 12.8 | 56.8 ± 11.4 | 54.8 ± 16.6 | 64 ± 0 | 57.2 ± 12.3 |
| Sex: Female, Male(Participants) | Sunitinib 25 mg CDD + S-1 + Cisplatin | Sunitinib 25 mg 2/2 + S-1 + Cisplatin (All) | Sunitinib 37.5 mg 2/2 + S-1 + Cisplatin | Sunitinib 12.5 mg CDD + S-1 + Cisplatin | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 1 | 8 |
| Male | 2 | 13 | 4 | 0 | 19 |
The record gives a start of Nov 2007, a primary completion of Jul 2009 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2015, 5 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cisplatin · Sunitinib